The chronic pain treatment market size has grown strongly in recent years. It will grow from $99.64 billion in 2024 to $109.05 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to the aging population, increasing prevalence of chronic diseases, heightened awareness of pain management, growth in prescription opioid use, and expansion of health insurance coverage.
The chronic pain treatment market size is expected to see strong growth in the next few years. It will grow to $155.0 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to a shift toward non-opioid alternatives, increased government funding for pain research, rising demand for personalized medicine, growing adoption of digital pain management tools, and expanding use of AI in pain diagnosis and treatment planning. Major trends during this period include advancements in neuromodulation therapies, integration of telemedicine into pain care, development of cannabinoid-based treatments, emphasis on multidisciplinary treatment approaches, and the rise of wearable pain monitoring devices.
The rising prevalence of arthritis pain is expected to significantly drive the growth of the chronic pain treatment market in the coming years. Arthritis pain, characterized by discomfort, aching, or soreness in the joints due to inflammation or degeneration, is increasingly common as the global population ages. The natural wear and tear on joints over time leads to a higher incidence of arthritis-related conditions, thereby increasing the demand for effective chronic pain management. Treatments targeting inflammation and nerve sensitivity help reduce pain, improve joint function, and enhance the quality of life for those suffering from persistent arthritis symptoms. For example, in March 2023, the Office for Health Improvement and Disparities, a UK government department, reported that 17.6% of individuals aged 16 and older had a long-term musculoskeletal condition, such as arthritis or chronic joint problems, in 2022 - an increase from 17% in 2021. Consequently, this growing prevalence is a key factor propelling the chronic pain treatment market forward.
Major companies operating in the chronic pain treatment market are focusing on developing innovative products like rechargeable spinal cord stimulators to improve patient convenience and enhance long-term pain management outcomes. A rechargeable spinal cord stimulator is an implantable medical device placed near the spine that delivers electrical pulses to disrupt pain signals, with the added benefit of being externally rechargeable, eliminating the need for additional surgeries. This technology helps manage chronic pain by blocking pain pathways in the spinal cord, thus reducing pain perception in patients suffering from conditions such as failed back surgery syndrome and neuropathic pain. For example, in December 2022, Abbott Laboratories, a US-based medical device company, launched the Eterna spinal cord stimulation system. Compact and discreet - smaller than an Apple AirPods case - this device offers significant pain relief, has shown potential in reducing opioid dependence, and is designed for minimally invasive, long-term use, ultimately improving patients’ daily functioning and quality of life.
In May 2025, electroCore Inc., a US-based bioelectronic technology company, acquired NeuroMetrix Inc. for an undisclosed amount. Through this acquisition, electroCore aims to bolster its leadership in the non-invasive bioelectronic therapy market by integrating NeuroMetrix’s Quell platform, thereby expanding its product portfolio and accelerating growth in the chronic pain and wellness sectors - especially within the Veterans Affairs (VA) Hospital System. NeuroMetrix Inc., based in the US, specializes in developing non-invasive therapeutic devices targeting chronic pain conditions like fibromyalgia.
Major players in the chronic pain treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Medtronic plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Mallinckrodt plc, and Nevro Corp.
North America was the largest region in the chronic pain treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in chronic pain treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the chronic pain treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Chronic pain treatment involves ongoing management of pain lasting longer than three months, often extending beyond normal healing time. It typically combines medications, physical therapy, psychological support, and lifestyle modifications to reduce pain severity, improve functional abilities, and enhance overall quality of life.
The primary product types in chronic pain treatment include drugs and devices. Drugs for chronic pain work by targeting inflammation, nerve signaling, or underlying causes to alleviate persistent pain and improve patient outcomes. These medications address a variety of conditions such as neuropathic pain, arthritis, chronic back pain, cancer-related pain, migraine, fibromyalgia, and more. They are distributed through multiple channels, including both direct and indirect methods, and are utilized by a diverse set of end users including hospitals, clinics, nursing homes, research institutions, and universities.
The chronic pain treatment market research report is one of a series of new reports that provides chronic pain treatment market statistics, including the chronic pain treatment industry global market size, regional shares, competitors with the chronic pain treatment market share, detailed chronic pain treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic pain treatment industry. These chronic pain treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The chronic pain treatment market consists of revenues earned by entities by providing services such as pharmacological treatment, physical therapy, psychological counseling, interventional pain management, alternative therapies, pain management clinics, and telehealth services. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic pain treatment market also includes sales of lyrica, cymbalta, oxycontin, neurontin, voltaren gel, quell, and precision spectra spinal cord stimulator. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The chronic pain treatment market size is expected to see strong growth in the next few years. It will grow to $155.0 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to a shift toward non-opioid alternatives, increased government funding for pain research, rising demand for personalized medicine, growing adoption of digital pain management tools, and expanding use of AI in pain diagnosis and treatment planning. Major trends during this period include advancements in neuromodulation therapies, integration of telemedicine into pain care, development of cannabinoid-based treatments, emphasis on multidisciplinary treatment approaches, and the rise of wearable pain monitoring devices.
The rising prevalence of arthritis pain is expected to significantly drive the growth of the chronic pain treatment market in the coming years. Arthritis pain, characterized by discomfort, aching, or soreness in the joints due to inflammation or degeneration, is increasingly common as the global population ages. The natural wear and tear on joints over time leads to a higher incidence of arthritis-related conditions, thereby increasing the demand for effective chronic pain management. Treatments targeting inflammation and nerve sensitivity help reduce pain, improve joint function, and enhance the quality of life for those suffering from persistent arthritis symptoms. For example, in March 2023, the Office for Health Improvement and Disparities, a UK government department, reported that 17.6% of individuals aged 16 and older had a long-term musculoskeletal condition, such as arthritis or chronic joint problems, in 2022 - an increase from 17% in 2021. Consequently, this growing prevalence is a key factor propelling the chronic pain treatment market forward.
Major companies operating in the chronic pain treatment market are focusing on developing innovative products like rechargeable spinal cord stimulators to improve patient convenience and enhance long-term pain management outcomes. A rechargeable spinal cord stimulator is an implantable medical device placed near the spine that delivers electrical pulses to disrupt pain signals, with the added benefit of being externally rechargeable, eliminating the need for additional surgeries. This technology helps manage chronic pain by blocking pain pathways in the spinal cord, thus reducing pain perception in patients suffering from conditions such as failed back surgery syndrome and neuropathic pain. For example, in December 2022, Abbott Laboratories, a US-based medical device company, launched the Eterna spinal cord stimulation system. Compact and discreet - smaller than an Apple AirPods case - this device offers significant pain relief, has shown potential in reducing opioid dependence, and is designed for minimally invasive, long-term use, ultimately improving patients’ daily functioning and quality of life.
In May 2025, electroCore Inc., a US-based bioelectronic technology company, acquired NeuroMetrix Inc. for an undisclosed amount. Through this acquisition, electroCore aims to bolster its leadership in the non-invasive bioelectronic therapy market by integrating NeuroMetrix’s Quell platform, thereby expanding its product portfolio and accelerating growth in the chronic pain and wellness sectors - especially within the Veterans Affairs (VA) Hospital System. NeuroMetrix Inc., based in the US, specializes in developing non-invasive therapeutic devices targeting chronic pain conditions like fibromyalgia.
Major players in the chronic pain treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Medtronic plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Mallinckrodt plc, and Nevro Corp.
North America was the largest region in the chronic pain treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in chronic pain treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the chronic pain treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Chronic pain treatment involves ongoing management of pain lasting longer than three months, often extending beyond normal healing time. It typically combines medications, physical therapy, psychological support, and lifestyle modifications to reduce pain severity, improve functional abilities, and enhance overall quality of life.
The primary product types in chronic pain treatment include drugs and devices. Drugs for chronic pain work by targeting inflammation, nerve signaling, or underlying causes to alleviate persistent pain and improve patient outcomes. These medications address a variety of conditions such as neuropathic pain, arthritis, chronic back pain, cancer-related pain, migraine, fibromyalgia, and more. They are distributed through multiple channels, including both direct and indirect methods, and are utilized by a diverse set of end users including hospitals, clinics, nursing homes, research institutions, and universities.
The chronic pain treatment market research report is one of a series of new reports that provides chronic pain treatment market statistics, including the chronic pain treatment industry global market size, regional shares, competitors with the chronic pain treatment market share, detailed chronic pain treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic pain treatment industry. These chronic pain treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The chronic pain treatment market consists of revenues earned by entities by providing services such as pharmacological treatment, physical therapy, psychological counseling, interventional pain management, alternative therapies, pain management clinics, and telehealth services. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic pain treatment market also includes sales of lyrica, cymbalta, oxycontin, neurontin, voltaren gel, quell, and precision spectra spinal cord stimulator. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Chronic Pain Treatment Market Characteristics3. Chronic Pain Treatment Market Trends And Strategies4. Chronic Pain Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market32. Global Chronic Pain Treatment Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Chronic Pain Treatment Market34. Recent Developments In The Chronic Pain Treatment Market
5. Global Chronic Pain Treatment Growth Analysis And Strategic Analysis Framework
6. Chronic Pain Treatment Market Segmentation
7. Chronic Pain Treatment Market Regional And Country Analysis
8. Asia-Pacific Chronic Pain Treatment Market
9. China Chronic Pain Treatment Market
10. India Chronic Pain Treatment Market
11. Japan Chronic Pain Treatment Market
12. Australia Chronic Pain Treatment Market
13. Indonesia Chronic Pain Treatment Market
14. South Korea Chronic Pain Treatment Market
15. Western Europe Chronic Pain Treatment Market
16. UK Chronic Pain Treatment Market
17. Germany Chronic Pain Treatment Market
18. France Chronic Pain Treatment Market
19. Italy Chronic Pain Treatment Market
20. Spain Chronic Pain Treatment Market
21. Eastern Europe Chronic Pain Treatment Market
22. Russia Chronic Pain Treatment Market
23. North America Chronic Pain Treatment Market
24. USA Chronic Pain Treatment Market
25. Canada Chronic Pain Treatment Market
26. South America Chronic Pain Treatment Market
27. Brazil Chronic Pain Treatment Market
28. Middle East Chronic Pain Treatment Market
29. Africa Chronic Pain Treatment Market
30. Chronic Pain Treatment Market Competitive Landscape And Company Profiles
31. Chronic Pain Treatment Market Other Major And Innovative Companies
35. Chronic Pain Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Chronic Pain Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on chronic pain treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for chronic pain treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic pain treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Product Type: Drugs; Devices2) By Indication: Neuropathic Pain; Arthritis Pain; Chronic Back Pain; Cancer Pain; Migraine; Fibromyalgia; Other Indications
3) By Distribution channels: Direct; Indirect
4) By End-User: Hospitals; Clinics; Nursing Homes; Research Centers And Universities; Other End-Users
Subsegments:
1) By Drugs: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Opioids; Antidepressants; Anticonvulsants; Muscle Relaxants; Topical Analgesics; Other Pain Relief Medications2) By Devices: Neuromodulation Devices; Transcutaneous Electrical Nerve Stimulation (TENS) Devices; Spinal Cord Stimulators; Peripheral Nerve Stimulators; Radiofrequency Ablation Devices; Implantable Drug Delivery Devices
Key Companies Profiled: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Sanofi S.A.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
- Merck & Co. Inc.
- AbbVie Inc.
- Bayer AG
- Sanofi S.A.
- Bristol-Myers Squibb Company
- AstraZeneca plc
- Abbott Laboratories
- Novartis AG
- GlaxoSmithKline plc
- Medtronic plc
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Boehringer Ingelheim International GmbH
- Boston Scientific Corporation
- Bausch Health Companies Inc.
- Sun Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals LLC
- Mallinckrodt plc
- Nevro Corp.